by admin_63069 | Feb 1, 2023 | Related Topics
Prostate specific membrane antigen (PSMA) PET/MRI can determine whether cancer is likely to return within two years after prostatectomy in men recently diagnosed with intermediate or high-grade prostate cancer.
by admin_63069 | Jan 30, 2023 | Related Topics
In this interview, Kevin Shee, MD, PhD, discusses the background key findings of the Journal of Urology study Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading but Not Adverse Pathology or Recurrence After Radical Prostatectomy.
by admin_63069 | Jan 26, 2023 | Related Topics
Expert oncologists Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, reflect on the current treatment paradigm for patients with metastatic castration-resistant prostate cancer (mCRPC).
by admin_63069 | Jan 23, 2023 | Related Topics
Based on current studies and anecdotal evidence, many of today’s urologists think it’s relatively safe to administer testosterone replacement in hypogonadal men on active surveillance or in those who have been treated with prostatectomy or cryosurgery.
by admin_63069 | Jan 19, 2023 | Related Topics
An overview of the steps involved in the clinical application of mpMRI imaging, from image generation to results interpretation and follow-up.
by admin_63069 | Jan 16, 2023 | Related Topics
Is abiraterone (Zytiga) a game changer for men with high-risk prostate cancer? A new study suggests that when combined with other drugs it is.
